BR0213357A - Compostos orgânicos - Google Patents
Compostos orgânicosInfo
- Publication number
- BR0213357A BR0213357A BR0213357-1A BR0213357A BR0213357A BR 0213357 A BR0213357 A BR 0213357A BR 0213357 A BR0213357 A BR 0213357A BR 0213357 A BR0213357 A BR 0213357A
- Authority
- BR
- Brazil
- Prior art keywords
- organic compounds
- cardiovascular
- center
- diseases
- prophylaxis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
"COMPOSTOS ORGâNICOS". A invenção refere-se a um sal formado de pelo menos um antagonista de receptor de AT~ 1~ tendo pelo menos um centro ácido e de pelo menos um ingrediente cardiovascular tendo pelo menos um centro básico que pode ser usado para tratamento de doenças e condições cardiovasculares, sua profilaxia ou retardo da progressão.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33033701P | 2001-10-18 | 2001-10-18 | |
PCT/EP2002/011652 WO2003035046A2 (en) | 2001-10-18 | 2002-10-17 | Salts formed of an at1-receptor antagonist and a cardiovascular agent |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0213357A true BR0213357A (pt) | 2004-10-26 |
Family
ID=23289311
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0213357-1A BR0213357A (pt) | 2001-10-18 | 2002-10-17 | Compostos orgânicos |
Country Status (8)
Country | Link |
---|---|
US (1) | US20040266836A1 (pt) |
EP (1) | EP1448190A2 (pt) |
JP (1) | JP2005509631A (pt) |
CN (1) | CN1571668A (pt) |
AU (1) | AU2002363087A1 (pt) |
BR (1) | BR0213357A (pt) |
CA (1) | CA2463758A1 (pt) |
WO (1) | WO2003035046A2 (pt) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA05012299A (es) * | 2003-05-16 | 2006-01-30 | Novartis Ag | Composicion farmaceutica que comprende valsartan. |
US20050187262A1 (en) * | 2004-01-12 | 2005-08-25 | Grogan Donna R. | Compositions comprising (S)-amlodipine and an angiotensin receptor blocker and methods of their use |
AR048431A1 (es) * | 2004-03-17 | 2006-04-26 | Novartis Ag | Formulaciones galenicas de compuestos organicos |
US20080161321A1 (en) * | 2004-03-17 | 2008-07-03 | David Louis Feldman | Use of Renin Inhibitors in Therapy |
WO2007056324A2 (en) * | 2005-11-08 | 2007-05-18 | Novartis Ag | Combination of an angiotensin ii receptor blocker, a calcium channel blocker and another active agent |
AR057882A1 (es) | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
GB0624087D0 (en) * | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril combination salt |
US20100292335A1 (en) * | 2007-02-16 | 2010-11-18 | Campbell Duncan J | Use of organic compounds |
EA020103B1 (ru) | 2009-01-23 | 2014-08-29 | Ханми Сайенс Ко., Лтд. | Твердая фармацевтическая композиция, содержащая амлодипин и лозартан, и способ ее получения |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5498636A (en) * | 1992-03-13 | 1996-03-12 | Ribogene, Inc. | Treatment of angina pectoris |
MY119161A (en) * | 1994-04-18 | 2005-04-30 | Novartis Ag | Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities |
DE19531463A1 (de) * | 1995-08-26 | 1997-02-27 | Merck Patent Gmbh | Pharmazeutische Zubereitung |
DE19607395C2 (de) * | 1996-02-28 | 2002-11-21 | Lohmann Therapie Syst Lts | Salze aus einem kationischen narkotischen Analgetikum mit einem anionischen nichtnarkotischen Analgetikum, Verfahren zu deren Herstellung und die diese Salze enthaltenden pharmazeutischen Präparate |
SG142116A1 (en) * | 1998-07-10 | 2008-05-28 | Novartis Ag | Antihypersensitive combination of valsartan and calcium channel blocker |
US6204281B1 (en) * | 1998-07-10 | 2001-03-20 | Novartis Ag | Method of treatment and pharmaceutical composition |
BR0007686A (pt) * | 1999-01-26 | 2001-11-06 | Novartis Ag | Uso de antagonistas receptores da angiotensina ii para tratar enfartação miocárdia aguda |
SE9901295D0 (sv) * | 1999-04-13 | 1999-04-13 | Jan Hedner | Sätt och medel för att förebygga, behandla och diagnostisera kardiovaskulära komplikationer hos patienter med obstruktiv sömnapné |
HN2000000050A (es) * | 1999-05-27 | 2001-02-02 | Pfizer Prod Inc | Sal mutua de amlodipino y atorvastatina |
US8168616B1 (en) * | 2000-11-17 | 2012-05-01 | Novartis Ag | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
-
2002
- 2002-10-17 WO PCT/EP2002/011652 patent/WO2003035046A2/en not_active Application Discontinuation
- 2002-10-17 AU AU2002363087A patent/AU2002363087A1/en not_active Abandoned
- 2002-10-17 EP EP02801896A patent/EP1448190A2/en not_active Withdrawn
- 2002-10-17 JP JP2003537613A patent/JP2005509631A/ja active Pending
- 2002-10-17 CA CA002463758A patent/CA2463758A1/en not_active Abandoned
- 2002-10-17 CN CNA028203879A patent/CN1571668A/zh active Pending
- 2002-10-17 US US10/493,040 patent/US20040266836A1/en not_active Abandoned
- 2002-10-17 BR BR0213357-1A patent/BR0213357A/pt not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2003035046A3 (en) | 2003-12-24 |
JP2005509631A (ja) | 2005-04-14 |
EP1448190A2 (en) | 2004-08-25 |
US20040266836A1 (en) | 2004-12-30 |
CN1571668A (zh) | 2005-01-26 |
CA2463758A1 (en) | 2003-05-01 |
AU2002363087A1 (en) | 2003-05-06 |
WO2003035046A2 (en) | 2003-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0314052A (pt) | Imidazolpiridinas e métodos para sua fabricação e uso | |
NO330934B1 (no) | Flytende farmasoytisk preparat samt anvendelse og fremstilling derav. | |
BR0209957A (pt) | Composto, processo para a preparação de um composto, composição farmacêutica que compreende um composto, utilização desse composto e processo para o tratamento e profilaxia de artrite, diabetes, distúrbios alimentares e obesidade | |
BRPI0316532B8 (pt) | composições farmacêuticas compreendendo uma droga básica ou ácida, um tensoativo, e um ácido ou base solúvel em água fisiologicamente tolerável | |
BR0308243A (pt) | Composto, formulação farmacêutica, e, métodos de tratar diabetes, doença de alzheimer, e de inibir gsk-3 em um mamìfero | |
BR0112160A (pt) | Agentes antiinflamatórios seletivos para glicocorticóides | |
BR0211119A (pt) | Composto, método de tratar um paciente que tenha, ou de prevenir um paciente de pegar, uma doença ou condição, uso de um composto, e, método para fabricar um composto | |
EA200501274A1 (ru) | Пиразолы и способы их получения и применения | |
MA25809A1 (fr) | Derives d'arylmethylamine pour usage comme inhibiteurs de tryptase | |
EA200300834A1 (ru) | Антагонисты фактора, высвобождающего кортикотропин | |
BR0213355A (pt) | composições farmacêuticas | |
BR0008664A (pt) | Métodos para o tratamento de, e para prevenir oucontrolar, distúrbios gastrointestinais,disfunção da motilidade gastrointestinal, emese, edoença de refluxo gastro-esofagiano em umpaciente, e, composição farmacêutica | |
BR0109703A (pt) | Derivados de piperazina | |
BR9916307A (pt) | Derivados quinolina | |
BR0211274A (pt) | Combinação de um antagonista de receptor de aldosterona e um inibidor de hmg co-a redutase | |
PL402389A1 (pl) | Sposób hamowania aktywnosci kinazy Raf u ludzi lub zwierzat | |
MA29316B1 (fr) | Derives de la diosmetine pour le traitement et la prevention des pathologies thrombotiques | |
BR0008687A (pt) | Métodos para o tratamento de, e para prevenir ou controlar, distúrbios gastrointestinais, disfunção da motilidade gastrointestinal, emese, e doença de refluxo gastro-esofageano em um paciente, e, composição farmacêutica | |
BR9811099A (pt) | Inibidores de urocinase | |
DE69912279D1 (de) | 5-ht1f agonisten | |
AR038207A1 (es) | Composicion farmaceutica dispersable oralmente de agomelatina | |
UY26851A1 (es) | Derivados de la 4-fenilpiridina | |
BR0213357A (pt) | Compostos orgânicos | |
DK2009025T3 (da) | Fremgangsmåde til hæmning af osteoklast-aktivitet | |
CY1111905T1 (el) | Φαρμακευτικη συνθεση περιλαμβανουσα εναν επιλεκτικο αναστολεα της αμινοπεπτιδασης α, ειδικα τον ec33, για τη μειωση της αρτηριακης πιεσεως |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |